News
HC Wainwright & Co. Reiterates Buy on BioLine Rx, Maintains $21 Price Target
17 Apr 24
News, Price Target, Reiteration, Analyst Ratings
BioLineRx Announces $6M Registered Direct Offering Of 7.5M ADS And Warrants To Purchase Up To An Aggregate Of 7.5M ADSs, At A Combined Purchase Price Of $0.80 Per ADS And Accompanying Warrant
1 Apr 24
News, Offerings
HC Wainwright & Co. Reiterates Buy on BioLine Rx, Maintains $21 Price Target
26 Mar 24
News, Price Target, Reiteration, Analyst Ratings
BioLine Rx Q4 EPS $(0.15) Beats $(0.22) Estimate, Sales $4.80M
26 Mar 24
Earnings, News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
26 Mar 24
Movers
Earnings Scheduled For March 26, 2024
26 Mar 24
Earnings
Earnings Preview For BioLine Rx
25 Mar 24
Earnings
HC Wainwright & Co. Reiterates Buy on BioLine Rx, Maintains $21 Price Target
29 Feb 24
News, Price Target, Reiteration, Analyst Ratings
Press releases
BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting
17 Apr 24
Press Releases
BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale Production
4 Mar 24
Press Releases
BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC)
28 Feb 24
Small Cap, Press Releases
BioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA® (motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT® and CIBMTR®
16 Feb 24
Press Releases